Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (4 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (1)
Type
(
2 selected
)
Type
Guidance (10)
Quality standard (0)
Guidance programme
(
1 selected
)
Guidance programme
Technology appraisal guidance (10)
Apply filters
Showing 1 to 10 of 10
multiple myeloma
Remove multiple myeloma filter
Type: Guidance
Remove Type: Guidance filter
Type: Quality standard
Remove Type: Quality standard filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance and quality standards awaiting development
Title
Type
Daratumumab for treating high-risk smouldering
multiple myeloma
[ID6214]
Technology appraisal guidance
Daratumumab in combination for untreated
multiple myeloma
when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249
Technology appraisal guidance
Idecabtagene vicleucel for treating relapsed or refractory
multiple myeloma
after 2 to 4 therapies TS ID 10330
Technology appraisal guidance
Isatuximab in combination as induction therapy for untreated
multiple myeloma
when an autologous stem cell transplant is suitable TS ID 11949
Technology appraisal guidance
Isatuximab in combination for newly diagnosed
multiple myeloma
[ID3981]
Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated
multiple myeloma
after autologous stem cell transplant [ID1517]
Technology appraisal guidance
REGN5458 for treating relapsed or refractory
multiple myeloma
TS ID 10443
Technology appraisal guidance
Selinexor with dexamethasone for treating relapsed or refractory
multiple myeloma
after 4 or more treatments [ID6193]
Technology appraisal guidance
Talquetamab for treating relapsed or refractory
multiple myeloma
after 3 therapies [ID 5082]
Technology appraisal guidance
Teclistamab with daratumumab for treating relapsed or refractory
multiple myeloma
after 1 or more therapies [ID6201]
Technology appraisal guidance
Current page
1
Page
1
of
1
Results per page
10
25
50
All
Back to top